NASDAQ: BIORBiora Therapeutics Inc Stock
$1.17+0.01 (+0.86%)
Updated Dec 8, 2023
BIOR Price
$1.17
Fair Value Price
$3.95
Market Cap
$27.73M
52 Week Low
$1.05
52 Week High
$7.68
P/E
-0.12x
P/B
-0.23x
P/S
1,811.31x
PEG
N/A
Dividend Yield
N/A
Revenue
$18.00k
Earnings
-$122.42M
Gross Margin
100%
Operating Margin
-619,444.44%
Profit Margin
-680,133.3%
Debt to Equity
-1.29
Operating Cash Flow
-$46M
Beta
1.4
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BIOR Overview
Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract and diagnose GI diseases, such as small intestine bacterial overgrowth through the development of various technologies to diagnose at the site of the disease. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BIOR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BIOR ($1.17) is undervalued by 70.36% relative to our estimate of its Fair Value price of $3.95 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
BIOR ($1.17) is significantly undervalued by 70.36% relative to our estimate of its Fair Value price of $3.95 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
BIOR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BIOR due diligence checks available for Premium users.
Be the first to know about important BIOR news, forecast changes, insider trades & much more!
BIOR News
Valuation
BIOR fair value
Fair Value of BIOR stock based on Discounted Cash Flow (DCF)
Price
$1.17
Fair Value
$3.95
Undervalued by
70.36%
BIOR ($1.17) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BIOR ($1.17) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BIOR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BIOR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.12x
Industry
11.7x
Market
31.32x
BIOR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.23x
Industry
5.42x
BIOR's financial health
Profit margin
Revenue
$0.0
Net Income
-$73.5M
Profit Margin
0%
BIOR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
BIOR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$34.7M
Liabilities
$153.5M
Debt to equity
-1.29
BIOR's short-term liabilities ($69.54M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BIOR's long-term liabilities ($83.95M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BIOR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BIOR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.0M
Investing
-$1.0k
Financing
-$2.8M
BIOR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BIOR vs Biotech Stocks
Biora Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.